AILERON THERAPEUTICS INC: Diferență între versiuni

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
(Pagină nouă: Pagina dedicata companiei AILERON THERAPEUTICS INC listata cu simbolul US.ALRN ==Descriere companie== Aileron Therapeutics, Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout th...)
 
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).)
 
Linia 2: Linia 2:


==Descriere companie==
==Descriere companie==
Aileron Therapeutics, Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors.
[[Aileron Therapeutics]], Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to [[PROTECT|protect]] multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors.


==Grafic actiuni companie==
==Grafic actiuni companie==
Utilizator anonim